12:00 AM
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

4-factor prothrombin complex concentrate: Phase IIIb data

CSL's CSL Behring subsidiary reported data from an open-label Phase IIIb trial in 212 patients showing that 4-factor PCC met the co-primary endpoint of non-inferiority to plasma, the standard of care, in the adequacy of stopping an ongoing major bleed at 24 hours in patients requiring urgent...

Read the full 214 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >